2Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics,2002 [J]. CA CancerJ Clin,2005,55(2):74 108.
3Tew WP,Kelsen DP, Ilson DH. Targeted therapies for esopha- geal cancer [J]. Oncologist, 2005,10(8) : 59-60.35 39.
4Dohmoto K, Hojo S, Fujita J, et al. Mechanisms of the release of CYFRA21-1 in human lung cancer cell lines [J]. Lung Cancer, 2000,30(1) ~55-63.
5Sheard MA, Vojtesek B, Simickova M, et al. Release of cytokera- tin-18 and -19 fragments (TPS and CYFRA 21-1) into the extra- cellular space during apoptosis [J]. J Cell Bioehem,2002,85(4) : 670 677.
6Wakatsuki M, Suzuki Y, Nakamoto S, et al. Clinical usefulness of CYFRA 21-1 for esophageal squamous cell carcinoma in radia tiontherapy [J]. J Gastroenterol Hepatol, 2007,22(5)~715 719.
7Yi Y, Li B, Wang Z, et al. CYFRA21-1 and CEA are useful markers for predicting the sensitivity to chemoradiotherapy of e- sophageal squamous cell carcinoma [J]. Biomarkers, 2009, 14 (7) =480 485.
8Nakamura T,Ide H,Eguchi R, et al. CYFRA 21-1 as a tumor marker for squamous cell carcinoma of the esophagus[J]. Dis E- sophagus,1998,11(1)~:35 39.
9Nozoe T,Rikimaru T,Mori E,et al. Increase in both CEA and CA19 9 in sera is an independent prognostic indicator in colorec tal carcinomaEJ]. J Surg Oncol, 2006,94(2) 132-137.
10ParkBW,OhJW,KimJH,et al. PreoperativeCA15 3 and CEA serum levels as predictor for breast cancer outcomesEJ~. Ann Oncol,2008,19(4) ,675-681.
